PROTIER
Biotech Inc.
PROTIER Biotech is leading the way in developing treatments for incurable diseases through innovative biotechnology.
“PROTIER Biotech is a company leading the development of cures for incurable diseases through innovative biotechnology. We are driven by a passion for challenges and new medicines to develop patient-centered therapies. We aim to introduce best-in-class therapeutics and contribute to improving the quality of life of patients and promoting human health. PROTIER Biotech will continue to create new value through innovation in science and technology, and to be a socially responsible company.”
CEO Profile
After earning his PhD in structural biology from Korea University, Dr. Kim has been active in the field of new drug R&D at leading pharmaceutical companies.
He led innovative drug development projects at CrystalGenomics as head of the Bio division and discovered many new drug candidates at AUTOTAC Bio as head of Chemistry R&D Center. With this wealth of experience, he became CEO of PROTIER Biotech in 2022.
Our Vision & Mission
"Challenge" and "passion for new drugs" are the core values of our corporate management. Based on this, we strive to develop patient-centered therapies and create a corporate culture that fulfills our social responsibilities.
We also respect the creativity and expertise of our employees, and we are creating a horizontal and collaborative organizational culture. This will enable PROTIER Biotech to achieve sustainable growth.
History
2024
July Received Venture Business Certification (2024-2027)
2024
June Completed Seed investment
2022
May Established Protier Biotech Co., Ltd.
Key Member
Hyuntae Kim
Founder & CEO | Ph.D.
HyunTae Kim founded Protier Biotech in May 2022. He experienced more than 20 years in pharmaceutical and biotech industry in area including R&D and pre-clinical development.
Background
PhD at Korea University
Head of Biology Dept. at Crystalgenomics
Head of Medicinal chemistry at AUTOTAC Bio
Key
Performances
-
Led multiple Structral-based drug design (SBDD) projects
-
Out-licensed small molecules in various projects
-
Led R&D and pre-clinical development of multiple small molecules
CSO | Ph.D., MBA
Jihyun Lee
JiHyun Lee joined Protier Biotech in April 2024 as Chief Strategy Officer. She has 19 years of experience in global pharmaceutical companies and biotech and has experience in various therapeutic areas.
Background
PhD at University of Illinois at Chicago
Postdoctoral Fellow at Stanford University, University of California at San Francisco
MBA at Korea University
Drug development team at CrystalGenomics
Medical Scientific/BD at Pfizer & Sanofi
Global Marketing Center at Seegene
Key
Performances
Led R&D projects
Managed medical/scientific role in various therapeutic areas